Acumen reports Q2 2026 results, reaffirms ALTITUDE-AD readout for late 2026
Acumen ended June with $110.2 million in cash and said its Phase 2 sabirnetug trial data are still expected this year, with two new brain-delivery candidates moving toward a 2027 IND.
Acumen Pharmaceuticals reported second quarter 2026 financial results and a business update on August 12, 2026. The company said it expects to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in late 20261.
The trial, which is investigating sabirnetug in 542 participants, with 180 per cohort, testing two active doses of 35 mg/kg and 50 mg/kg given intravenously every four weeks against placebo over an 18-month double-blind period1, will report on several measures. Acumen said topline results are expected to include the iADRS primary efficacy endpoint, along with secondary measures such as CDR-SB, safety data including ARIA rates, and key biomarkers1.
On the pipeline side, Acumen said in June 2026 it nominated two development candidates, ACU301 and ACU401, as part of the exercise of Acumen's option under its license agreement with JCR Pharmaceuticals1. In July 2026 the company presented data at the Alzheimer's Association International Conference showing that in non-human primates, ACU401 achieved up to 40-fold greater frontal cortex exposure along with a significant increase in exposure in deep brain regions1. The company also said no hematological safety signals, including no effects on reticulocytes, were observed in non-human primates, pointing to a low potential for anemia1.
Acumen is targeting submission of an IND for a lead EBD program candidate in mid-20271.
On finances, cash, cash equivalents and marketable securities totaled $110.2 million as of June 30, 2026, down from $128.4 million as of March 31, 20261. R&D expenses were $27.8 million versus $37.1 million a year earlier, a decline the company attributed to reductions in manufacturing and materials costs, and CRO costs, both associated with the ALTITUDE-AD trial1. Net loss for the quarter was $32.7 million, compared with $41.0 million in the prior-year quarter for the quarter ended June 30, 20251. The company said its cash position is expected to support current clinical and operational activities into early 20271.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.